Human VHL Alexa Fluor® 594-conjugated Antibody

Applications

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Preparation and Storage

Background: VHL

VHL (von Hippel-Lindau disease tumor suppressor) is the substrate recognition subunit for an E3 ligase activity that ubiquitinates proteins containing hydroxyproline residues.  Targets of VHL include HIF1 alpha, beta 2 adrenergic receptor, ZHX2 and others.  In VHL-box E3 Ubiquitin ligases, VHL is bound to a heterodimer complex composed of Elongin B (ELOB) and Elongin C (ELOC) through the "BC-box motif" found in many proteins in the VHL-box and SOCS-box protein families.  ELOB/ELOC serves as an adapter between substrate recognition proteins and Cullin-2 (or Cullin-5) and RBX1 to form an active E3 ligase.  

Product Datasheets

Related Research Areas

• Ubiquitin-related Molecules in the Akt Pathway